NetworkNewsBreaks – Endonovo Therapeutics, Inc.
Post# of 416
(Total Views: 936)
Posted On: 02/10/2020 3:03:10 PM
NetworkNewsBreaks – Endonovo Therapeutics, Inc. (ENDV) Collaborates with Major Universities for the Evaluation of SofPulse(R) for Orthopedic Surgeries
Endonovo Therapeutics (OTCQB: ENDV) today announced the evaluation of its SofPulse(R) device at major universities for orthopedic surgeries. Endonovo’s FDA-Cleared SofPulse(R) is a non-invasive device utilized for the reduction of postoperative pain and edema and represents a low-cost drug-free solution for reducing opioid usage, accelerating patient recovery and preventing opioid addiction following surgical procedures. “We are pleased to announce SofPulse(R) is now being evaluated at major medical universities. We believe this is a unique opportunity for SofPulse(R) to be evaluated, and upon completion and approval, be used as a standard of healthcare moving forward,” Endonovo Therapeutics CEO Alan Collier said in the news release. “We are also optimistic SofPulse(R) can be used by professors as a standard medical device which can be implemented in the educational process for all medical professionals. Although we are in the early stages, the university administrators and professors are expediting the evaluation process.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Endonovo Therapeutics (OTCQB: ENDV) today announced the evaluation of its SofPulse(R) device at major universities for orthopedic surgeries. Endonovo’s FDA-Cleared SofPulse(R) is a non-invasive device utilized for the reduction of postoperative pain and edema and represents a low-cost drug-free solution for reducing opioid usage, accelerating patient recovery and preventing opioid addiction following surgical procedures. “We are pleased to announce SofPulse(R) is now being evaluated at major medical universities. We believe this is a unique opportunity for SofPulse(R) to be evaluated, and upon completion and approval, be used as a standard of healthcare moving forward,” Endonovo Therapeutics CEO Alan Collier said in the news release. “We are also optimistic SofPulse(R) can be used by professors as a standard medical device which can be implemented in the educational process for all medical professionals. Although we are in the early stages, the university administrators and professors are expediting the evaluation process.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)